Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia

Blood (2024) 143 (26): 2804–2807.

https://doi.org/10.1182/blood.2024024452

Published: 2024

Includes: Supplemental data

Journal Articles

Low Tmtv Influences Response and Outcomes in R/R DLBCL 3L+ Patients Treated with CAR-T Cells : First Results of FDG-PET/CT Analysis in the French Descar-T Registry

Yassine Al Tabaa, Clément Bailly, Xavier Pallard, Anne Ségolène Cottereau, Jérémie Tordo, Pierre Sesques, Guillaume Cartron, Roch Houot, Roberta Di Blasi, Salim Kanoun, Caroline Milin, Françoise Kraeber-Bodéré, Laetitia Vercellino

Blood (2023) 142 (Supplement 1): 3019.

https://doi.org/10.1182/blood-2023-185794

Published: 2023

Journal Articles

Invasive Fungal Infections after CAR T-Cell Therapy for B-Cell Lymphoma: A Study from the French Descart Registry

Blood (2023) 142 (Supplement 1): 2140.

https://doi.org/10.1182/blood-2023-185632

Published: 2023

Journal Articles

Outcomes of High-Grade B-Cell Lymphoma As Compared to Other Large B-Cell Lymphoma Subtypes in Patients Treated with CD19-Directed CAR-T Cells at 3 rd Line or More. a Lysa Study Based on the French Descart-Registry.

Xavier Phina-Ziebin, Emmanuel Bachy, Francois Xavier Gros, Roberta Di Blasi, Charles Herbaux, Jacques-Olivier Bay, Sylvain Carras, Pierre Bories, René-Olivier Casasnovas, Fabrice Jardin, Franck Morschhauser, Blandine Guffroy, Elodie Gat, Julien Calvani, Marie Parrens, Elsa Poullot, Alexandra Traverse-Glehen, Louise Roulin

Blood (2023) 142 (Supplement 1): 3112.

https://doi.org/10.1182/blood-2023-180707

Published: 2023

Journal Articles

CD19-Targeting CAR T-Cell Therapy in Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Descar-T and US Collaborative Study

Eric Durot, Damien Roos-Weil, Adrien Chauchet, Justine Decroocq, Roberta Di Blasi, Thomas Gastinne, Hedi Bensader, Morgane Cheminant, Caroline Jacquet, Stephanie Guidez, François-Xavier Gros, Emmanuel Bachy, Pascale Cony-Makhoul, Steven P Treon, Alain Jacques Delmer, Ran Reshef, Steven Le Gouill, Jorge J. Castillo, Roch Houot

Blood (2023) 142 (Supplement 1): 616.

https://doi.org/10.1182/blood-2023-173988

Published: 2023

Journal Articles

Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

Blood (2023) 142 (10): 865–877.

https://doi.org/10.1182/blood.2023020578

Published: 2023

Includes: Supplemental data

Journal Articles

Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

Livio Pagano, Jon Salmanton-García, Francesco Marchesi, Ola Blennow, Maria Gomes da Silva, Andreas Glenthøj, Jaap van Doesum, Yavuz M. Bilgin, Alberto López-García, Federico Itri, Raquel Nunes Rodrigues, Barbora Weinbergerová, Francesca Farina, Giulia Dragonetti, Caroline Berg Venemyr, Jens van Praet, Ozren Jaksic, Toni Valković, Iker Falces-Romero, Sonia Martín-Pérez, Moraima Jiménez, Julio Dávila-Valls, Martin Schönlein, Emanuele Ammatuna, Stef Meers, Mario Delia, Zlate Stojanoski, Anna Nordlander, Tobias Lahmer, László Imre Pinczés, Caterina Buquicchio, Klára Piukovics, Irati Ormazabal-Vélez, Nicola Fracchiolla, Michail Samarkos, Gustavo-Adolfo Méndez, José-Ángel Hernández-Rivas, Ildefonso Espigado, Martin Cernan, Verena Petzer, Sylvain Lamure, Roberta di Blasi, Joyce Marques de Almedia, Michelina Dargenio, Monika M. Biernat, Mariarita Sciumè, Cristina de Ramón, Nick de Jonge, Josip Batinić, Avinash Aujayeb, Monia Marchetti, Guillemette Fouquet, Noemí Fernández, Giovanni Zambrotta, Maria Vittoria Sacchi, Anna Guidetti, Fatih Demirkan, Lucia Prezioso, Zdeněk Ráčil, Marcio Nucci, Miloš Mladenović, Raphaël Liévin, Michaela Hanáková, Stefanie Gräfe, Uluhan Sili, Marina Machado, Chiara Cattaneo, Tatjana Adžić-Vukičević, Luisa Verga, Jorge Labrador, Laman Rahimli, Matteo Bonanni, Francesco Passamonti, Antonio Pagliuca, Paolo Corradini, Martin Hoenigl, Philipp Koehler, Alessandro Busca, Oliver A. Cornely

Blood (2022) 140 (26): 2773–2787.

https://doi.org/10.1182/blood.2022017257

Published: 2022

Includes: Supplemental data

Journal Articles

Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis

Blood (2022) 140 (24): 2584–2593.

https://doi.org/10.1182/blood.2022016945

Published: 2022

Journal Articles

Late Failure of Aggressive B-Cell Lymphoma Following CAR T-Cell Therapy: A Lysa Study from the Descar-T Registry

Federico Erbella, Emmanuel Bachy, Guillaume Cartron, Elodie Gat, Franck Morschhauser, Benoit Tessoulin, Olivier Tournilhac, Choquet Sylvain, François-Xavier Gros, Cristina Castilla-Llorente, Arnaud Campidelli, René-Olivier Casasnovas, Louise Roulin, Pierre Bories, Mohamad Mohty, Martin Carre, Steven Le Gouill, Roch Houot, Roberta Di Blasi

Blood (2022) 140 (Supplement 1): 1325–1327.

https://doi.org/10.1182/blood-2022-165352

Published: 2022

Journal Articles

A Propensity Score-Matched Comparison of Axi-Cel and Tisa-Cel for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Real-Life: A Lysa Study from the Descar-T Registry

Blood (2021) 138 (Supplement 1): 92.

https://doi.org/10.1182/blood-2021-150721

Published: 2021

Journal Articles

Outcome of Relapsed/Refractory Aggressive B-Cell Lymphoma Patients Relapsing after Anti-CD19 CAR T-Cells and Enrolled in the Descar-T French National Registry

Blood (2021) 138 (Supplement 1): 885.

https://doi.org/10.1182/blood-2021-150994

Published: 2021

Journal Articles

Poor Outcome of Patients with COVID-19 after CAR T-Cell Therapy for B-Cell Malignancies: Results from a Multicenter Study on Behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

Blood (2021) 138 (Supplement 1): 2818.

https://doi.org/10.1182/blood-2021-149466

Published: 2021

Journal Articles

Lenalidomide Exposure at Time of CAR T-Cells Expansion Enhances Response of Refractory/Relapsed Aggressive Large B-Cell Lymphomas

Jean Lemoine, Florence Morin, Roberta Di Blasi, Laetitia Vercellino, Alexis Cuffel, Naoufal Benlachgar, Jerome Larghero, Isabelle Madelaine, Julien Calvani, Veronique Meignin, Sophie Caillat-Zucman, Sylvie Chevret, Catherine Thieblemont

Blood (2021) 138 (Supplement 1): 1433.

https://doi.org/10.1182/blood-2021-151109

Published: 2021

Journal Articles

Kte-X19 in Relapsed or Refractory Mantle-Cell Lymphoma, a "Real-Life" Study from the Descar-T Registry and Lysa Group

Blood (2021) 138 (Supplement 1): 743.

https://doi.org/10.1182/blood-2021-148626

Published: 2021

Journal Articles

Lenalidomide Enhance CAR T-Cells Response in Patients with Refractory/Relapsed Large B Cell Lymphoma Experiencing Progression after Infusion

Catherine Thieblemont, MD PhD, Sylvie Chevret, MD PhD, Vincent Allain, Roberta Di Blasi, Florence Morin, Laetitia Vercellino, Sandrine Roulland, PhD, Karin Tarte, PhDPharmD, Veronique Meignin, Sophie Caillat-Zucman, MD PhD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-136279

Published: 2020

Journal Articles

TEAM Conditioning (Thiotepa, Etoposide, Cytarabine, Melphalan) Prior to Autologous Hematopoietic Stem Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Final Results from a Prospective Multicenter Study

Rémy Duléry, MD, Laure Lebras, MD, Sylvain Choquet, MD, Roberta Di Blasi, Ahmad Kanj AL Jijakli, Laurence Heuberger, Eolia Brissot, MD PhD, Giorgia Battipaglia, MD, Florent Malard, MD PhD, Clemence Mediavilla, MD, Anne Vekhoff, MD, Paul Coppo, MD PhD, Tounes Ledraa, MD, Zora Marjanovic, Elise Corre, MD, Simona Lapusan, MD, Malek Aoudjhane, MD, Ramdane Belhocine, Mohamad Mohty, MD PhD

Blood (2019) 134 (Supplement_1): 786.

https://doi.org/10.1182/blood-2019-130651

Published: 2019

Journal Articles

Impact of Bridging Chemotherapy on Clinical Outcomes of CD19 CAR T Therapy in Relapse/Refractory Diffuse Large B- Cell Lymphoma in Real World Experience

Jérôme Paillassa, MD, Laetitia Vercellino, Roberta Di Blasi, Sophie Bernard, Hannah Moatti, MD, Côme Bommier, Matteo Guerra, Veronique Meignin, Sylvie Chevret, Catherine Thieblemont, MD PhD

Blood (2019) 134 (Supplement_1): 2886.

https://doi.org/10.1182/blood-2019-129421

Published: 2019

Journal Articles

CD19 CAR T-Cell Therapy in Patients with Relapse/Refractory DLBCL: Retrospective Analysis of the Eligibility Criteria

Blood (2019) 134 (Supplement_1): 2887.

https://doi.org/10.1182/blood-2019-129532

Published: 2019

Journal Articles

Seifem 2016 Study: Incidence of Probable and Proven Invasive Aspergillosis in Patients with Acute Myeloid Leukemia during Consolidation Therapy

Maria Ilaria Del Principe, Roberta di Blasi, MD, Luisa Verga, MD, Anna Candoni, MD, Stelvio Ballanti, MD, Leonardo Potenza, Chiara Cattaneo, MD, Mario Delia, MD, Nunzia Decembrino, MD, Lorella MA Melillo, MD, Carlo Castagnola, MD, Gianpaolo Nadali, MD, Rosa Fanci, MD, Antonella Ferrari, MD, Nicola Fracchiolla, MD, Enrico Orciuolo, PhD MD, Federica Lessi, MD, Anna Chierichini, MD, Massimo Offidani, MD, Marco Picardi, MD, Lucia Prezioso, MD, Benedetta Rambaldi, MD, Francesco Marchesi, MD, Ombretta Annibali, Daniele Zama, MD, Valentina Mancini, MD, Prassede Salutari, MD, Maria Grazia Garzia, MD, Adriana Vacca, MD, Simone Cesaro, MD, Rosangela Invernizzi, MD, Katia Perruccio, MD, Maria Enza Mitra, MD, Angela Maria Quinto, MD, Maria Chiara Tisi, Bruno Martino, Adriano Venditti, MD, Alessandro Busca, Franco Aversa, MD, Livio Pagano, MD

Blood (2017) 130 (Supplement 1): 5018.

https://doi.org/10.1182/blood.V130.Suppl_1.5018.5018

Published: 2017

Journal Articles

Bloodstream Infections in Hematological Cancer Patients Colonized By Multiresistant Bacteria: Final Results of a Multicentric Prospective Observational Seifem Study

Blood (2016) 128 (22): 3700.

https://doi.org/10.1182/blood.V128.22.3700.3700

Published: 2016

NARROW

High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia

Low Tmtv Influences Response and Outcomes in R/R DLBCL 3L+ Patients Treated with CAR-T Cells : First Results of FDG-PET/CT Analysis in the French Descar-T Registry

Invasive Fungal Infections after CAR T-Cell Therapy for B-Cell Lymphoma: A Study from the French Descart Registry

Outcomes of High-Grade B-Cell Lymphoma As Compared to Other Large B-Cell Lymphoma Subtypes in Patients Treated with CD19-Directed CAR-T Cells at 3 rd Line or More. a Lysa Study Based on the French Descart-Registry.

CD19-Targeting CAR T-Cell Therapy in Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Descar-T and US Collaborative Study

Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis

Late Failure of Aggressive B-Cell Lymphoma Following CAR T-Cell Therapy: A Lysa Study from the Descar-T Registry

A Propensity Score-Matched Comparison of Axi-Cel and Tisa-Cel for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Real-Life: A Lysa Study from the Descar-T Registry

Outcome of Relapsed/Refractory Aggressive B-Cell Lymphoma Patients Relapsing after Anti-CD19 CAR T-Cells and Enrolled in the Descar-T French National Registry

Poor Outcome of Patients with COVID-19 after CAR T-Cell Therapy for B-Cell Malignancies: Results from a Multicenter Study on Behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

Lenalidomide Exposure at Time of CAR T-Cells Expansion Enhances Response of Refractory/Relapsed Aggressive Large B-Cell Lymphomas

Kte-X19 in Relapsed or Refractory Mantle-Cell Lymphoma, a "Real-Life" Study from the Descar-T Registry and Lysa Group

Lenalidomide Enhance CAR T-Cells Response in Patients with Refractory/Relapsed Large B Cell Lymphoma Experiencing Progression after Infusion

TEAM Conditioning (Thiotepa, Etoposide, Cytarabine, Melphalan) Prior to Autologous Hematopoietic Stem Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Final Results from a Prospective Multicenter Study

Impact of Bridging Chemotherapy on Clinical Outcomes of CD19 CAR T Therapy in Relapse/Refractory Diffuse Large B- Cell Lymphoma in Real World Experience

CD19 CAR T-Cell Therapy in Patients with Relapse/Refractory DLBCL: Retrospective Analysis of the Eligibility Criteria

Seifem 2016 Study: Incidence of Probable and Proven Invasive Aspergillosis in Patients with Acute Myeloid Leukemia during Consolidation Therapy

Bloodstream Infections in Hematological Cancer Patients Colonized By Multiresistant Bacteria: Final Results of a Multicentric Prospective Observational Seifem Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only